XRHealth Acquires PursueCare Expanding Addiction Treatment Options

BOSTON, Nov. 9, 2026 /CourierPR/ -- XRHealth, a leading platform for therapeutic technologies, has expanded its reach into personalized virtual addiction treatment with the acquisition of PursueCare. This move aims to address the significant gap in substance use disorder treatment, particularly in the United States.

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), in 2025, 44.6 million Americans aged 12 or older had a substance use disorder, with 89% of these individuals receiving no substance use treatment. Behavioral health provider shortages, stigma, and cost constraints often hinder access to care, leaving patients without the comprehensive, engaging support they need. PursueCare was founded to tackle these barriers by providing compassionate, judgment-free treatment designed around the realities of patients' lives.

Through the acquisition, XRHealth will provide patients with access to licensed addiction clinicians, therapists, counselors, psychiatrists, and case managers through secure telehealth and mobile-based services. This model connects patients with care teams directly from a smartphone app, reaching beyond limited community resources and reducing the long wait times, travel, time off work, and childcare arrangements that can make ongoing treatment difficult.

PursueCare's care model combines medical care, behavioral health, medications, and software-based treatments tailored to each patient's needs. Services may include medications for opioid use disorder, therapy and counseling, cognitive behavioral therapy (CBT), psychiatric care, and case management to address transitions from hospitals, prisons, and other treatment settings and connect patients with community resources for primary care, housing, transportation, food security, and other common barriers.

XRHealth has also acquired PursueCare's FDA-authorized prescription digital therapeutics, RESET® and RESET-O®. These digital therapeutics deliver evidence-based cognitive behavioral therapy and contingency management through a smartphone. RESET® is indicated to increase abstinence and treatment retention in adults with substance use disorder, as an adjunct to contingency management. RESET-O® is indicated to increase retention in outpatient treatment for adults with opioid use disorder by providing cognitive behavioral therapy alongside treatment that includes buprenorphine and contingency management, under clinician supervision. Patients can use these software-based treatments to practice recovery skills between visits, while clinicians can review engagement and patient-reported progress.

By joining XRHealth, PursueCare will become part of an established virtual care ecosystem that includes immersive VR support groups, where patients can use avatars to participate with greater privacy and anonymity. This creates new opportunities to combine PursueCare's personalized addiction care with XRHealth's immersive VR support groups and expand how patients engage with treatment and peer support.

XRHealth is licensed across 40 U.S. states and serves patients through Medicare Part B, VA programs, and expanding commercial insurance pathways. The company's vision is to make personalized healthcare more accessible and seamlessly connected across the digital devices people use every day.